

Experiment Number: C20614-01
Test Type: TOX
Route: Dosing in Feed
Species/Strain: Rat/Sprague Dawley

PA48: Summary of Tissue Concentration
Test Compound: Perfluorooctanoic Acid
CAS Number: 335-67-1

Date Report Requested: 04/23/2018
Time Report Requested: 09:44:27
Lab: NTP

C Number:	C20614-01
Cage Range:	All
Date Range:	All
Reasons For Removal:	All
Removal Date Range:	All
Treatment Groups:	All
Study Gender:	Both

Experiment Number: C20614-01

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Sprague Dawley

PA48: Summary of Tissue Concentration

Test Compound: Perfluorooctanoic Acid

CAS Number: 335-67-1

Date Report Requested: 04/23/2018

Time Report Requested: 09:44:27

Lab: NTP

F1 Male: Non-Perinatal

Phase	Dose (ppm)	0/0	0/150	0/300
SD 109	Plasma Concentration (ng/ml)	BD	193000 ± 11325 (10)	242500 ± 12731 (10)
SD 109	Plasma Concentration (uM)	BD	466.1 ± 27.4 (10)	585.7 ± 30.7 (10)
SD 109	Liver Concentration (ng/g)	BD	157400 ± 5418 (10)	171000 ± 7578 (10)
SD 109	Liver Concentration (uM)	BD	380.1 ± 13.1 (10)	413.0 ± 18.3 (10)
SD 109	Liver/Plasma Ratio	BD	0.84 ± 0.05 (10)	0.73 ± 0.06 (10)

Experiment Number: C20614-01
Test Type: TOX
Route: Dosing in Feed
Species/Strain: Rat/Sprague Dawley

PA48: Summary of Tissue Concentration
Test Compound: Perfluorooctanoic Acid
CAS Number: 335-67-1

Date Report Requested: 04/23/2018
Time Report Requested: 09:44:27
Lab: NTP

		F1 Male: Perinatal		
Phase	Dose (ppm)	0/0	150/150	300/300
SD 109	Plasma Concentration (ng/ml)	BD	175390 ± 14956 (10)	223400 ± 8422 (10)
SD 109	Plasma Concentration (uM)	BD	423.6 ± 36.1 (10)	539.5 ± 20.3 (10)
SD 109	Liver Concentration (ng/g)	BD	144300 ± 5752 (10)	193800 ± 9704 (10)
SD 109	Liver Concentration (uM)	BD	348.5 ± 13.9 (10)	468.0 ± 23.4 (10)
SD 109	Liver/Plasma Ratio	BD	0.86 ± 0.06 (10)	0.88 ± 0.05 (10)

Experiment Number: C20614-01

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Sprague Dawley

PA48: Summary of Tissue Concentration

Test Compound: Perfluorooctanoic Acid

CAS Number: 335-67-1

Date Report Requested: 04/23/2018

Time Report Requested: 09:44:27

Lab: NTP

F1 Female: Non-Perinatal

Phase	Dose (ppm)	0/0	0/300	0/1000
SD 109	Plasma Concentration (ng/ml)	BD	20420 ± 1212 (10)	72250 ± 4351 (10)
SD 109	Plasma Concentration (uM)	BD	49.3 ± 2.9 (10)	174.5 ± 10.5 (10)
SD 109	Liver Concentration (ng/g)	BD	16420 ± 787 (10)	69040 ± 3942 (10)
SD 109	Liver Concentration (uM)	BD	39.7 ± 1.9 (10)	166.7 ± 9.5 (10)
SD 109	Liver/Plasma Ratio	BD	0.82 ± 0.03 (10)	0.96 ± 0.04 (10)

Experiment Number: C20614-01
Test Type: TOX
Route: Dosing in Feed
Species/Strain: Rat/Sprague Dawley

PA48: Summary of Tissue Concentration
Test Compound: Perfluorooctanoic Acid
CAS Number: 335-67-1

Date Report Requested: 04/23/2018
Time Report Requested: 09:44:27
Lab: NTP

		F1 Female: Perinatal		
Phase	Dose (ppm)	0/0	150/300	300/1000
SD 109	Plasma Concentration (ng/ml)	BD	20800 ± 1043 (10)	70160 ± 6895 (10)
SD 109	Plasma Concentration (uM)	BD	50.2 ± 2.5 (10)	169.4 ± 16.7 (10)
SD 109	Liver Concentration (ng/g)	BD	16660 ± 750 (10)	67840 ± 5681 (10)
SD 109	Liver Concentration (uM)	BD	40.2 ± 1.8 (10)	163.8 ± 13.7 (10)
SD 109	Liver/Plasma Ratio	BD	0.81 ± 0.03 (10)	0.99 ± 0.05 (10)

Experiment Number: C20614-01

Test Type: TOX

Route: Dosing in Feed

Species/Strain: Rat/Sprague Dawley

PA48: Summary of Tissue Concentration

Test Compound: Perfluorooctanoic Acid

CAS Number: 335-67-1

Date Report Requested: 04/23/2018

Time Report Requested: 09:44:27

Lab: NTP

LEGEND

Data are displayed as mean \pm SEM (N) unless otherwise noted

SD – Study Day; GD – Gestation Day; LD – Lactation Day; PND – Postnatal Day

If over 20% of the animals in a group are above the limit of detection, then 1/2 the limit of detection value is substituted for values that are below the limit of detection.

When the control group did not have over 20% of its values above the limit of detection, no mean or standard error were calculated; no statistical analysis was done for the endpoint.

Statistical analysis performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests (unless otherwise noted).

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at $P \leq 0.05$

** Statistically significant at $P \leq 0.01$

Values adjusted for molar concentration were calculated by dividing by the molecular weight of 414.06.

Statistically significant at $P \leq 0.05$ for male multiple comparisons of 0/150 to 150/150 and 0/300 to 300/300 using a Wilcoxon rank-sum test with a Hommel p-value adjustment.

Statistically significant at $P \leq 0.01$ for male multiple comparisons of 0/150 to 150/150 and 0/300 to 300/300 using a Wilcoxon rank-sum test with a Hommel p-value adjustment.

\$ Statistically significant at $P \leq 0.05$ for female multiple comparisons of 0/300 to 150/300 and 0/1000 to 300/1000 using a Wilcoxon rank-sum test with a Hommel p-value adjustment.

\$\$ Statistically significant at $P \leq 0.01$ for female multiple comparisons of 0/300 to 150/300 and 0/1000 to 300/1000 using a Wilcoxon rank-sum test with a Hommel p-value adjustment.

Decrease in N for Plasma Concentration in the 0/0 group is due to one male's value being excluded because it was an outlier.

BD Group did not have over 20% of its values above the limit of quantification

**** END OF REPORT ****